This randomized, placebo-controlled double blinded study examined whether placebo, low- or high dose omega 3 fatty acid supplementation had associations with mental health symptoms and vitamin D status in college students aged 18-27.

A 3-arm randomized design was employed where participants took 2 pills daily for 90 days. The first arm was a placebo, second arm was a low dose omega 3 and third arm was high dose omega 3. Mental health outcomes were measured using the GAD 7 questionnaire that measured anxiety, PHQ-9 which measured depression, and MSQ (Medical Symptoms Questionnaire) that assessed overall bodily symptoms. Vitamin D levels were also assessed as a secondary outcome.

Inclusion Criteria:

• age 18-27 years
• if taking antidepressants or enrolled in therapy, needs to be stable with at least 6 months or more of stable medication dose use and regular therapy appointments

Exclusion Criteria:

• age younger than 18 and older than 27
• not willing to take two capsules daily for 90 days
• not willing to get bloodwork
• has a history of fainting during bloodwork
• not willing to have anthropometrics measured
• not willing to have daily text reminders sent to phone
• currently has regularly taken omega 3 daily for at least 6 months
• currently has regularly taken vitamin D supplementation daily for at least 6 months
• allergic or sensitive to fish
• will not like to deal with potential "fish burps"
• utilized mental health services for less than 6 months
• taken an antidepressant for less than 6 months
• currently actively takes benzodiazepines
• currently actively takes sedatives or tranquilizers
• Currently is taking steroid supplements
• currently is taking steroid medications
• had surgery within the last 2 weeks or plans on having surgery within the next 3 months
• currently taking blood thinning medications
• takes NSAIDS regularly
• currently using a weight loss drug

De-identified dataset, along with the study protocol, statistical analysis plan, informed consent document, and clinical study report, will be made available to qualified researched upon reasonable request. Data will be provided for purposes of research synthesis, including systematic reviews and meta- analyses, following investigator approval and execution of a data use agreement. All shared materials will be de-identified and limited to variables necessary to address the approved research question.

After publication of primary results and within 3 years of that publication.

Access to de-identified individual participant data will be provided to qualified researchers for the purpose of inclusion in systematic reviews and meta-analyses. Requests must be addressed to the main and backup contacts (Dr Harris and Dr Hutchins) via email (and will be reviewed by the research team). Requests must include a brief research proposal, statistical analysis plan, and evidence of IRB approval or exemption, as applicable. Approved requests will receive the de-identified data and supporting documents via a secure electronic transfer following execution of a data use agreement.

The coordinators recruiting and measuring